Progression-Free Survival – Page 3 – Talk Bio

Actionable Insights Powered by AI

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

1 year ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)

GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma

1 year ago talkbio0Tagged Blenrep, Combined, GSK's, Multiple Myeloma, Progression-Free Survival, turnaround

Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined